Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 januari 07, 2019 om 12:00 PM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 januari 02, 2019 om 12:00 PM UTC